Who is sponsoring NCT04850430?

NCT04850430 is sponsored by University Hospital Heidelberg.

What drugs are being tested in NCT04850430?

Interventions in NCT04850430: Gastric venous reconstruction.

What condition does NCT04850430 study?

NCT04850430 studies Pancreas Cancer, Pancreatectomy.

Is NCT04850430 still recruiting?

NCT04850430 is currently status unknown. Last updated 13 December 2023.

Last reviewed 2023-12-13 · How we verify

NCT04850430: GENDER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gastric Venous Reconstruction After Total Pancreatectomy

Status unknown NA Last updated 13 December 2023

What this trial tests

NA trial testing Gastric venous reconstruction in Pancreas Cancer in 20 participants. Status unknown.

Timeline

1 February 2024

Primary endpoint
1 August 2024

1 December 2025

Quick facts

Lead sponsor	University Hospital Heidelberg
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	1 February 2024
Primary completion	1 August 2024
Estimated completion	1 December 2025
Sites	2 locations across Germany

Drugs / interventions tested

Gastric venous reconstruction

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →
Pancreatectomy — all drugs for Pancreatectomy →

Sponsor

University Hospital Heidelberg

Who can join

18 and older, any sex, with Pancreas Cancer or Pancreatectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Total pancreatoduodenectomy (TP) is the standard surgical approach for treatment of extended pancreas tumors. If the gastric coronary vein has to be sacrificed for oncologic or for technical reasons in total pancreatectomy with splenectomy, gastric venous congestion (GVC) may result because all major venous draining routes are terminated. In the sequelae of GVC, gastric venous infarction ultimately leads to gastric perforation with abdominal sepsis. To avoid gastric venous infarction, partial or even total gastrectomy is usually performed in the event of GVC after TP. However, this significantly impacts the patient's quality of life. Reconstruction of gastric venous outflow represents a technical approach to overcome GVC and to avoid gastric venous infarction making (partial) gastrectomy unnecessary. The current study aims to assess the role of gastric venous outflow reconstruction in GVC after TP to prevent (partial) gastrectomy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gastric venous reconstruction to reduce gastric venous congestion after total pancreatectomy: study protocol of a single-centre prospective non-randomised observational study (IDEAL Phase 2A) - GENDER study (Gastric vENous DrainagE Reconstruction).
Mehrabi A, Loos M, Ramouz A, Dooghaie Moghadam A, et al · · 2021 · cited 8× · PMID 34675020 · DOI 10.1136/bmjopen-2021-052745

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other University Hospital Heidelberg trials

Trials by the same sponsor.

NCT07388147 — Exercise Therapy for Multiple Myeloma Patients · NA · not yet recruiting
NCT07348874 — Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany · not yet recruiting
NCT07181928 — Is Mentalization-based Therapy More Effective Than Treatment-as-usual for Adolescents With Dissocial Disorders? · NA · not yet recruiting
NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
NCT06913010 — DV 100 as a Framework for the Hospital Incident Command System · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04850430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Heidelberg
Last refreshed: 13 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04850430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing